MAT Research, founded in 2016 and headquartered in The Netherlands, has developed a breakthrough in the realm of pyrogen testing with its innovative Monocyte Activation Test (MAT). By positioning itself as an animal-free alternative to the traditional Rabbit Pyrogen Test, the company is at the forefront of ethical and efficient pharmaceutical testing solutions.
This biotechnology firm, operating at the intersection of AI, Automation, Biotechnology, Life Sciences, Pharmaceutical, and Machine Learning, leverages its MAT to test parenteral drugs for both endotoxin and non-endotoxin contaminants. Using cryopreserved pooled PBMC, the test boasts high sensitivity and robustness, delivering reliable results. The MAT kit's comprehensive nature, complemented by consulting services and technical support, makes it a practical solution for organizations.
Despite no recent investments listed, MAT Research remains poised for growth, offering promising opportunities for investors seeking to support innovative, animal-free advancements in pharmaceutical testing.